|
Simple and Practical Method for the Quantitative High-Sensitivity Analysis of N-Nitroso Duloxetine in Duloxetine Drug Products Utilizing LC-MS/MS
|
|
0
|
707
|
March 9, 2024
|
|
AI limit for N-Nitroso Losartan
|
|
4
|
610
|
March 9, 2024
|
|
Is it possible to observe N-nitrosamines formation from oximes? Do you have any reference to support the risk assessment for nitrosamine formation from the reaction of these functional groups in the presence of nitrosating agents? Thank you
|
|
2
|
304
|
February 27, 2024
|
|
In Silico Prediction of Pharmaceutical Degradation Pathways: A Benchmarking Study Using the Software Program Zeneth
|
|
3
|
412
|
February 24, 2024
|
|
Testig method for nitroso Ciprofloxacin
|
|
12
|
1445
|
February 16, 2024
|
|
NDSRIs standards (for confirmatory testing or ames/other tests)
|
|
15
|
1389
|
February 14, 2024
|
|
Defining nitrosamine acceptable intake based on technical feasibible limit rather than CPCA
|
|
6
|
488
|
February 11, 2024
|
|
N- nitroso Nitazoxanide
|
|
1
|
508
|
February 8, 2024
|
|
Aromatic nitrogen "Is it possible for aromatic nitrogen to convert nitrosamine?"- Indole
|
|
10
|
2154
|
February 2, 2024
|
|
Nitrosamine Impurities in Topical Drug Product
|
|
3
|
616
|
February 3, 2024
|
|
Adoption of CPCA beyond FDA/ EMA
|
|
9
|
1005
|
January 31, 2024
|
|
🇪🇺 EMA/409815/2020 Rev.20
|
|
7
|
5081
|
January 31, 2024
|
|
Confidence score calculation for the carcinogenic potency categorization approach (CPCA) predictions for N-nitrosamines
|
|
5
|
1262
|
January 11, 2024
|
|
Exploring the CPCA Framework: Defining Acceptable Intake for NDSRIs -Event
|
|
2
|
894
|
January 10, 2024
|
|
🇹🇼 Taiwan Food and Drug Administration on Nitroso - Salbutamol
|
|
0
|
524
|
January 9, 2024
|
|
Reflective Beginnings: We have to be in the driver's seat
|
|
4
|
555
|
January 9, 2024
|
|
N-nitroso Torasemide Impurity formation and control
|
|
23
|
1860
|
January 5, 2024
|
|
NDSRI in metronidazole
|
|
1
|
799
|
December 28, 2023
|
|
Redefining Nitrosamine Risks: A Fresh Perspective on Pharmaceuticals -Pub
|
|
16
|
2335
|
December 17, 2023
|
|
MDD for API/DP for Ophthalmic Formulation
|
|
4
|
923
|
December 12, 2023
|
|
Control of NDSRIs impurity at Drug Substance (API) specification
|
|
8
|
1307
|
December 5, 2023
|
|
10º encontro Farmacopeia Brasileira
|
|
0
|
515
|
November 30, 2023
|
|
CPCA Calculation System (Python Desktop)
|
|
1
|
1412
|
November 22, 2023
|
|
🇨🇭 Swiss Medic Guidelines
|
|
7
|
1680
|
November 20, 2023
|
|
🇪🇺 EMA - Enhanced AMES test conditions
|
|
0
|
771
|
November 15, 2023
|
|
Review of NDSRIs in Pharmaceutical Drugs -Pub
|
|
1
|
864
|
November 13, 2023
|
|
AI for NDSRIs with positive EAT and/or in-vivo mutagenicity study - FDA position?
|
|
2
|
644
|
November 9, 2023
|
|
Vilazodone Nitrosamine
|
|
0
|
445
|
October 31, 2023
|
|
Review of nitrosamine drug substance related impurities (ndsri) in pharmaceutical drugs
|
|
1
|
741
|
October 31, 2023
|
|
Personal perspective on N-Nitrosamines and recent revision of guidelines
|
|
7
|
797
|
October 27, 2023
|